World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
39124
World Ranking
12951
National Ranking
6623

Michael J. Morris publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael J. Morris sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 534 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael J. Morris D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. Morris sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael J. Morris is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on the medical field, with significant contributions in pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, oncology, cancer research, and molecular biology.

The scientist's work covers a variety of main topics, including:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Medical Imaging Techniques and Applications
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Michael J. Morris has published extensively in well-known venues, with frequent publications appearing in:

  • Journal of Clinical Oncology
  • European Urology
  • Clinical Cancer Research
  • Annals of Oncology
  • The Journal of Urology

Notable recent papers include:

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, 2021, New England Journal of Medicine
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients, 2022, Cell
  • The Lancet Commission on prostate cancer: planning for the surge in cases, 2024, The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, 2021, Clinical Cancer Research

Frequent co-authors collaborating with Michael J. Morris include:

  • Oliver Sartor
  • Johann S. de Bono
  • Karim Fizazi
  • Howard I. Scher
  • Susan Halabi

Best Publications

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Organoid cultures derived from patients with advanced prostate cancer

    Dong Gao;Ian Vela;Andrea Sboner;Phillip J Iaquinta

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

    Howard I Scher;Tomasz M Beer;Celestia S Higano;Aseem Anand

  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Toni K. Choueiri;Susan Halabi;Ben L. Sanford;Olwen Hahn

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

    Wassim Abida;Michael L. Cheng;Joshua Armenia;Sumit Middha

  • Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

    Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan

  • Erratum: Integrative Clinical Genomics of Advanced Prostate Cancer

    Dan Robinson;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

    Wassim Abida;Joshua Armenia;Anuradha Gopalan;Ryan Brennan

  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

    Susan Halabi;Chen-Yen Lin;W. Kevin Kelly;Karim S. Fizazi

  • Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

    Scott T. Tagawa;Matthew I. Milowsky;Michael Morris;Shankar Vallabhajosula

  • Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

    William Kevin Kelly;Susan Halabi;Michael Carducci;Daniel George

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer

    Steven M Larson;Michael Morris;Ilonka Gunther;Brad Beattie

  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

    Toni K. Choueiri;Colin Hessel;Susan Halabi;Ben Sanford

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • Incidence of nephrogenic systemic fibrosis at two large medical centers.

    Martin R. Prince;Honglei Zhang;Michael Morris;Jennifer L. MacGregor

Frequent Co-Authors

Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Susan Halabi
Susan Halabi Duke University
Eric J. Small
Eric J. Small University of California, San Francisco
Glenn Heller
Glenn Heller Memorial Sloan Kettering Cancer Center
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Jorge A. Carrasquillo
Jorge A. Carrasquillo Memorial Sloan Kettering Cancer Center
Daniel J. George
Daniel J. George Duke University
Celestia S. Higano
Celestia S. Higano University of Washington
John L. Humm
John L. Humm Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or supplementary career pathways is a smart move for anyone interested in medicine or healthcare. Online degrees offer convenient options to advance your education and broaden your career opportunities in this fast-growing field.

For those aiming to become advanced practice providers, attending the cheapest np school can help reduce overall educational costs—an important factor considering the rising expense of healthcare education.

Many prospective nurses start by researching online nursing programs that offer flexibility and affordability, allowing students to balance study with work or family commitments.

Current RNs interested in furthering their education often look at the average cost of rn to bsn programs to determine how to advance their credentials without incurring excessive debt.

For those interested in leadership, teaching, or research positions, pursuing online nursing phd programs can open doors to high-level roles with significant impact on healthcare systems and patient outcomes.

With numerous affordable and flexible options available, online degrees present valuable pathways for launching or advancing a healthcare career in the USA.

Best Scientists Citing Michael J. Morris

Trending Scientists

Recently Published Articles